1.
Matt Spraker
@SprakerMDPhD
Hey #medtwitter
Here are the basics on unequal randomization in trials
Why should we do 1:1 instead of 2:1 or 3:1 in phase 3 RCTs?
Here are the basics on unequal randomization in trials
Why should we do 1:1 instead of 2:1 or 3:1 in phase 3 RCTs?
2.
Matt Spraker
@SprakerMDPhD
Boom!
Honored to have accepted a DEI achievement award on behalf of the UNC Department of Radiation Oncology fro… twitter.com/i/web/status/1…
Honored to have accepted a DEI achievement award on behalf of the UNC Department of Radiation Oncology fro… twitter.com/i/web/status/1…
3.
4.
5.
6.
7.
Matt Spraker
@SprakerMDPhD
TAP Episode Drop!
We interviewed @AmarUKishan and Brett Sloman (@85Apocalyptic) of @viewray to discuss the MIR… twitter.com/i/web/status/1…
We interviewed @AmarUKishan and Brett Sloman (@85Apocalyptic) of @viewray to discuss the MIR… twitter.com/i/web/status/1…
Matt Spraker
@SprakerMDPhD
Let's create a resource center for future #radonc residents!
Does your program offer scholarships or opportuni… twitter.com/i/web/status/1…
Does your program offer scholarships or opportuni… twitter.com/i/web/status/1…
Retweet of status by @ACROresident
Matt Spraker
@SprakerMDPhD
Go work for organizations that treat you like a hero. You deserve it.
Happy holidays #RadOnc
Happy holidays #RadOnc
Matt Spraker
@SprakerMDPhD
Oh hey, it's nearly the New Year and we've got some resolution ideas for ya to use in 2023 pic.twitter.com/OBgSSaYrzW
Retweet of status by @COParksWildlife
Matt Spraker
@SprakerMDPhD
My first Tweetorial 2 year toxicity results of PACE B published here. Big thanks to the andcollaborators a… twitter.com/i/web/status/1…
Retweet of status by @alison_tree
8.
9.
10.
11.
Matt Spraker
@SprakerMDPhD
Are you a #radonc looking for a high-quality PP opportunity in a cool place?
I *highly recommend* this practi… twitter.com/i/web/status/1…
I *highly recommend* this practi… twitter.com/i/web/status/1…
Retweet of status by @ErinGillespieMD
Matt Spraker
@SprakerMDPhD
Great study of RT v CRT in low risk nasopharyngeal cancer in JAMA!
P3 RCT
T2N0-1 or T3N0 NPX w/o adverse featur… twitter.com/i/web/status/1…
P3 RCT
T2N0-1 or T3N0 NPX w/o adverse featur… twitter.com/i/web/status/1…
Retweet of status by @DrChowdharyMD
Matt Spraker
@SprakerMDPhD
Is there a role for Local Tx of the Primary Tumor for Patients with Metastatic Cancer?
Many studies demonstrate n… twitter.com/i/web/status/1…
Many studies demonstrate n… twitter.com/i/web/status/1…
Retweet of status by @jryckman3
Matt Spraker
@SprakerMDPhD
#ASTROAdvocacy list
Ensure cont’d access through stable Medicare payments & an equitable, improved RO-APM… twitter.com/i/web/status/1…
Ensure cont’d access through stable Medicare payments & an equitable, improved RO-APM… twitter.com/i/web/status/1…
Retweet of status by @fumikochino
...but wait! There's more!
1.
fakhright
@fakhright
astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*
